 Aethlon Medical, Inc. Nasdaq: AEMD the Company, a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced the closing of the previously announced underwritten public offering of 3,333,334 shares of common stock which includes pre-funded warrants to purchase shares of common stock in lieu thereof, and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of 1.50 per share. Each share of common stock or pre-funded warrant in lieu thereof was sold together with a common warrant to purchase one share of common stock. The common warrants have an exercise price of 1.50 per share, are immediately exercisable, and will expire five years from the date of issuance. The Company has also granted the underwriter a 45-day option to purchase up to an additional 499,999 shares of common stock andor common warrants to purchase up to 499,999 shares of common stock, at the public offering price, less underwriting discounts and commission. 